Skip to main content

Table 2 Emerging treatments with potential for targeting atherogenic dyslipidaemia

From: Residual macrovascular risk in 2013: what have we learned?

  

Effects on atherogenic dyslipidaemia*

Other effects

Outstanding issues

Treatment group/example

Dose

Triglycerides

HDL-C

  

[reference]; duration

SPPARMs: K-877 [81]

100 μg BID

↓70%

↑18%

Improved safety profile (CV, renal and hepatic biomarkers) versus fenofibrate

Outcomes data, long-term safety

12 weeks

Dual PPAR agonists

     

GFT505 (dual PPARα/δ) [84]

80 mg OD

↓17-25%

↑8-9%

Improved safety profile (hepatic biomarkers)

Lower efficacy than current PPARα agonists

4 weeks

Outcomes data, long-term safety

CETP inhibitors

Anacetrapib1[85]

100 mg OD

↓7%

↑138%

Decreases in LDL-C (~40%), Lp(a) and apoB

Outcomes data, long-term safety

24 weeks

Evacetrapib1[86]

100 mg OD

NA

↑~80%

Decreases in LDL-C (36%); data on other lipid effects NA

Outcomes data, long-term safety

12 weeks

PCSK9 targeted therapy

     

Alirocumab1[87]

150 mg every 2 weeks

↓19%

↑6%

Decreases in LDL-C (>60%); also Lp(a) and apoB

Outcomes data, long-term safety

12 weeks

AMG 1451,2[88]

140 mg every 2 weeks

↓34%

↑8%

Decreases in LDL-C (>60%), Lp(a) and apoB

Outcomes data, long-term safety

12 weeks

  1. *Placebo-adjusted effect; 1Change from baseline in combination with a statin; 2AMG 145 is now referred to as evolocumab BID twice daily; apo apolipoprotein; CETP cholesteryl ester transfer protein; CV cardiovascular; LDL-C low-density lipoprotein cholesterol; Lp(a) lipoprotein(a); NA not available; OD once daily; PCSK9 proprotein convertase subtilisin/kexin type 9; PPAR peroxisome proliferator-activated receptor; SPPARMs Selective peroxisome proliferator-activated receptor modulators.